1. Market Research
  2. > Ardea Biosciences, Inc. – Product Pipeline Review – 2013

Ardea Biosciences, Inc. – Product Pipeline Review – 2013

  • May 2013
  • -
  • Global Markets Direct
  • -
  • 52 pages

Ardea Biosciences, Inc. – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “Ardea Biosciences, Inc. - Product Pipeline Review - 2013” provides data on the Ardea Biosciences, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Ardea Biosciences, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Ardea Biosciences, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Ardea Biosciences, Inc. - Brief Ardea Biosciences, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Ardea Biosciences, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Ardea Biosciences, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Ardea Biosciences, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Ardea Biosciences, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Ardea Biosciences, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Ardea Biosciences, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Ardea Biosciences, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Ardea Biosciences, Inc. and identify potential opportunities in those areas.

Table Of Contents

Ardea Biosciences, Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Ardea Biosciences, Inc. Snapshot 5
Ardea Biosciences, Inc. Overview 5
Key Information 5
Key Facts 5
Ardea Biosciences, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Ardea Biosciences, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Ardea Biosciences, Inc. - Pipeline Products Glance 10
Ardea Biosciences, Inc. - Late Stage Pipeline 10
Phase III Products/Combination Treatment Modalities 10
Ardea Biosciences, Inc. Clinical Stage Pipeline Products 11
Phase I Products/Combination Treatment Modalities 11
Ardea Biosciences, Inc. - Early Stage Pipeline Products 12
Pre-Clinical Products/Combination Treatment Modalities 12
Ardea Biosciences, Inc. - Drug Profiles 13
900 Series 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
lesinurad 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
RDEA-3170 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
RDEA-684 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
Ardea Biosciences, Inc. - Pipeline Products by Route of Administration 18
Ardea Biosciences, Inc. - Pipeline Products By Mechanism of Action 19
Ardea Biosciences, Inc. - Recent Pipeline Updates 20
Ardea Biosciences, Inc. - Dormant Projects 23
Ardea Biosciences, Inc. - Discontinued Pipeline Products 24
Discontinued Pipeline Product Profiles 24
iseganan hydrochloride 24
Ardea Biosciences, Inc. - Company Statement 25
Ardea Biosciences, Inc. - Locations And Subsidiaries 27
Head Office 27
Other Locations and Subsidiaries 27
Ardea Biosciences, Inc., Recent Developments 28
Ardea Biosciences, Inc.- Press Release 28
Jun 18, 2010: Ardea Presents Data From Proof-Of-Concept Study Examining Combination Of RDEA594 And Febuxostat For Treatment Of Hyperuricemia And Gout At EULAR Annual European Congress 28
Jun 18, 2010: Ardea Presents Interim Results From Phase Ib Study Of RDEA594 In Combination With Allopurinol For Treatment Of Hyperuricemia And Gout At EULAR Annual European Congress 28
Jun 18, 2010: Ardea Presents Positive Phase II Data On RDEA594 For Treatment Of Hyperuricemia And Gout At EULAR Annual European Congress 29
May 13, 2010: Ardea Biosciences To Present Additional Data On Gout Program At Annual European Congress Of Rheumatology 31
Mar 31, 2010: Ardea Announces Positive Top-Line Results From Phase IIb Study Of RDEA594 For Treatment Of Hyperuricemia In Gout Patients 31
Jan 07, 2010: Ardea Biosciences Announces Phase 2A Study Results Of RDEA594 For The Treatment Of Hyperuricemia And Gout 33
Financial Deals Landscape 34
Ardea Biosciences, Inc., Deals Summary 34
Ardea Biosciences, Inc., Pharmaceuticals and Healthcare, Deal Details 35
Licensing Agreements 35
Ardea Biosciences Enters Into License Agreement With Bayer HealthCare 35
Equity Offering 37
Ardea Biosciences Completes Public Offering Of Common Stock For US$166 Million 37
Ardea Biosciences Completes Exercise Of Underwriters' Over-allotment Option For US$82 Million 40
Ardea Biosciences Completes Public Offering Of US$80.5 Million 42
Ardea Biosciences Completes Private Placement Of US$31 Million 44
Ardea Biosciences Completes Private Placement US$40 Million 46
Acquisition 48
AstraZeneca Completes Acquisition Of Ardea Biosciences, Gout Drug Maker, For US$1.26 Billion 48
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 52
Disclaimer 52



List of Tables

Ardea Biosciences, Inc., Key Information 5
Ardea Biosciences, Inc., Key Facts 5
Ardea Biosciences, Inc. - Pipeline by Indication, 2013 7
Ardea Biosciences, Inc. - Pipeline by Stage of Development, 2013 8
Ardea Biosciences, Inc. - Monotherapy Products in Pipeline, 2013 9
Ardea Biosciences, Inc. - Phase III, 2013 10
Ardea Biosciences, Inc. - Phase I, 2013 11
Ardea Biosciences, Inc. - Pre-Clinical, 2013 12
Ardea Biosciences, Inc. - Pipeline By Route of Administration, 2013 18
Ardea Biosciences, Inc. - Pipeline Products By Mechanism of Action, 2013 19
Ardea Biosciences, Inc. - Recent Pipeline Updates, 2013 20
Ardea Biosciences, Inc. - Dormant Developmental Projects,2013 23
Ardea Biosciences, Inc. - Discontinued Pipeline Products, 2013 24
Ardea Biosciences, Inc., Subsidiaries 27
Ardea Biosciences, Inc., Deals Summary 34
Ardea Biosciences Enters Into License Agreement With Bayer HealthCare 35
Ardea Biosciences Completes Public Offering Of Common Stock For US$166 Million 37
Ardea Biosciences Completes Exercise Of Underwriters' Over-allotment Option For US$82 Million 40
Ardea Biosciences Completes Public Offering Of US$80.5 Million 42
Ardea Biosciences Completes Private Placement Of US$31 Million 44
Ardea Biosciences Completes Private Placement US$40 Million 46
AstraZeneca Completes Acquisition Of Ardea Biosciences, Gout Drug Maker, For US$1.26 Billion 48



List of Figures

Ardea Biosciences, Inc. - Pipeline by Indication, 2013 7
Ardea Biosciences, Inc. - Pipeline by Stage of Development, 2013 8
Ardea Biosciences, Inc. - Monotherapy Products in Pipeline, 2013 9
Ardea Biosciences, Inc. - Pipeline Products By Mechanism of Action, 2013 19

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.